We invite you to engage in an interactive roundtable with leading neurologists, researchers, and patients to help advance the discovery and implementation of ALS digital biomarkers in clinical trials through our collaborative efforts.
Joining our participatory roundtable, you will be the first to learn about our latest study results on ALS digital biomarkers as well as have the opportunity to hear why major pharmaceutical companies have joined the consortium to partner in our research, which will be expanded to include analyzing data from wearables and smartphones.
As always, we approach each roundtable to encourage out-of-the-box thinking, and to kick it off, we have an exciting agenda! Take a look below.
This is an invite only event.
Agenda
September 19, 2022 - 3:30PM EST, 12:30PM PST
10 minutes
5 minutes
15 minutes
20 minutes
13 minutes
14 minutes
3 minutes
Consoritia Updates, Partnerships
-
Indu Navar, EverythingALS
-
James Berry, Neurologist at Massachusetts General Hospital
Living with ALS, Diagnosed with ALS in 2022
Keynote: James Harshman
Amazon AWS Partnership to Grow Digital Start Up Ecosystem
Rishi Madhok, MD, Health Care Life Science VC & Startups @ AWS
Multi modal approach - Radcliff study
-
Meera Gandhi, Chief of Staff, EverythingALS
-
Alexis Mathieu, Cofounder and Senior Advisor, FeetMe
-
Shira Hahn, VP of Analytics, Aural Analytics
-
Mike DiCesare, President, ZEPHYRx
EverythingALS & Modality.ai Speech Study Updates
-
Alan Taitz & Julian Peller, EverythingALS Data Scientist
-
David Suendermann-Oeft , Modality.ai
Open discussion & Questions
Wendy, VP Global Head Patient Experience, Astra Zeneca
Closing remarks and next steps
Indu Navar, EverythingALS